AR071516A1 - Regimenes de dosificacion con antiprogestinas que comprende la administracion de un antagonista de progesterona como el compuesto cdb-4124 - Google Patents
Regimenes de dosificacion con antiprogestinas que comprende la administracion de un antagonista de progesterona como el compuesto cdb-4124Info
- Publication number
- AR071516A1 AR071516A1 ARP090101513A AR071516A1 AR 071516 A1 AR071516 A1 AR 071516A1 AR P090101513 A ARP090101513 A AR P090101513A AR 071516 A1 AR071516 A1 AR 071516A1
- Authority
- AR
- Argentina
- Prior art keywords
- progesterone antagonist
- woman
- compound
- methyl
- antiprogestines
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000044 progesterone antagonist Substances 0.000 title abstract 3
- JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 title abstract 2
- -1 methyloxy, formyloxy, acetoxy Chemical group 0.000 abstract 3
- 201000009273 Endometriosis Diseases 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 abstract 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 230000029849 luteinization Effects 0.000 abstract 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000027758 ovulation cycle Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4847208P | 2008-04-28 | 2008-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071516A1 true AR071516A1 (es) | 2010-06-23 |
Family
ID=40751037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101513 AR071516A1 (es) | 2008-04-28 | 2009-04-28 | Regimenes de dosificacion con antiprogestinas que comprende la administracion de un antagonista de progesterona como el compuesto cdb-4124 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8426394B2 (enExample) |
| EP (1) | EP2293797B1 (enExample) |
| JP (1) | JP5791499B2 (enExample) |
| KR (2) | KR20130059442A (enExample) |
| CN (2) | CN105616427A (enExample) |
| AR (1) | AR071516A1 (enExample) |
| AU (1) | AU2009241355B2 (enExample) |
| BR (1) | BRPI0911563A2 (enExample) |
| CA (1) | CA2722753C (enExample) |
| CL (1) | CL2009001010A1 (enExample) |
| DK (1) | DK2293797T3 (enExample) |
| EA (3) | EA201071249A1 (enExample) |
| ES (1) | ES2561810T3 (enExample) |
| IL (1) | IL208844A0 (enExample) |
| ME (1) | ME01123B (enExample) |
| MX (1) | MX2010011272A (enExample) |
| MY (1) | MY161059A (enExample) |
| NI (1) | NI201000183A (enExample) |
| NZ (1) | NZ589533A (enExample) |
| SG (1) | SG10201408483QA (enExample) |
| TW (1) | TWI477276B (enExample) |
| UA (1) | UA102849C2 (enExample) |
| WO (1) | WO2009134718A1 (enExample) |
| ZA (1) | ZA201007529B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| TWI539953B (zh) * | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
| HUP0900487A2 (hu) * | 2009-08-05 | 2011-03-28 | Richter Gedeon Nyrt | 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására |
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| EP2471537A1 (en) * | 2010-12-30 | 2012-07-04 | PregLem S.A. | Treatment of pain associated with dislocation of basal endometrium |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| EP2854763B1 (en) * | 2012-05-31 | 2018-09-26 | Repros Therapeutics Inc. | Formulations for vaginal delivery of antiprogestins |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP6343619B2 (ja) * | 2012-11-02 | 2018-06-13 | レプロス セラピューティクス インコーポレイティド | プロゲステロン依存性病態を処置する方法およびその組成物 |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| HU230381B1 (hu) * | 2014-02-17 | 2016-03-29 | Richter Gedeon Nyrt | Ipari eljárás szteroid intermedier előállítására |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| EP3174542A4 (en) | 2014-07-29 | 2018-01-03 | TherapeuticsMD, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (fr) * | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| ATE151286T1 (de) | 1983-11-14 | 1997-04-15 | Columbia Lab Inc | Bioadhäsive mittel |
| FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5439913A (en) * | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
| PL178174B1 (pl) * | 1993-11-16 | 2000-03-31 | Garfield Robert E | Kompozycje farmaceutyczne do hamowania kurczliwości macicy lub stymulowania kurczliwości macicy |
| DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| SK282570B6 (sk) * | 1995-02-02 | 2002-10-08 | Schering Aktiengesellschaft | Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania |
| DE69702450T2 (de) * | 1996-05-01 | 2001-03-08 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | 21-substituierte progesteron derivate als antigestagene |
| US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| AU2805397A (en) | 1996-08-30 | 1998-03-19 | Population Council, Center For Biomedical Research, The | Vaginal application mifepristone |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| US6172052B1 (en) | 1998-12-04 | 2001-01-09 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| DK1265911T3 (da) * | 2000-03-17 | 2008-09-29 | Us Gov Health & Human Serv | 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler |
| IN191020B (enExample) * | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| CA2405500C (en) | 2000-04-03 | 2006-08-22 | Astenjohnson, Inc. | Pre-crimped tie components |
| US7378406B2 (en) * | 2000-10-18 | 2008-05-27 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| DE60228583D1 (de) | 2001-07-09 | 2008-10-09 | Repros Therapeutics Inc | Verfahren und materialien für die behandlung des testosteron-mangels bei männern |
| US7833545B2 (en) | 2003-04-29 | 2010-11-16 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
| EP1593376A1 (en) | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| AU2005265357B2 (en) * | 2004-07-09 | 2011-04-07 | Laboratoire Hra Pharma | Sustained release compositions containing progesterone receptor modulators |
| GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| DE102005028970A1 (de) * | 2005-06-22 | 2006-12-28 | Siemens Ag | Piezoakter mit gesteigertem Hubvermögen |
| DE102005030294A1 (de) | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| US8173626B2 (en) * | 2006-03-08 | 2012-05-08 | Danco Laboratories Llc | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders |
| ES2643318T3 (es) | 2006-10-24 | 2017-11-22 | Repros Therapeutics Inc. | Composiciones y métodos para suprimir la proliferación endometrial |
| EP2125858A2 (en) * | 2007-01-17 | 2009-12-02 | Repros Therapeutics Inc. | Pharmaceutically acceptable salts of 11-(4-aminophenyl)-19-norpregna-4,9(10)-diene-3,20-dione derivatives |
| CA2682752C (en) | 2007-04-05 | 2015-07-07 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
| HRP20160689T1 (hr) * | 2007-04-20 | 2016-07-15 | Preglem S.A. | Selektivni modulatori progesterona za tretman uterinog krvarenja |
| TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| JP5992330B2 (ja) | 2009-09-29 | 2016-09-14 | メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ | 物質を投与するための子宮内電子カプセル |
-
2009
- 2009-04-09 TW TW098111780A patent/TWI477276B/zh not_active IP Right Cessation
- 2009-04-27 EA EA201071249A patent/EA201071249A1/ru unknown
- 2009-04-27 US US12/990,203 patent/US8426394B2/en not_active Expired - Fee Related
- 2009-04-27 MY MYPI2010004777A patent/MY161059A/en unknown
- 2009-04-27 CN CN201610029200.9A patent/CN105616427A/zh active Pending
- 2009-04-27 AU AU2009241355A patent/AU2009241355B2/en not_active Ceased
- 2009-04-27 BR BRPI0911563A patent/BRPI0911563A2/pt not_active Application Discontinuation
- 2009-04-27 MX MX2010011272A patent/MX2010011272A/es active IP Right Grant
- 2009-04-27 ES ES09739520.6T patent/ES2561810T3/es active Active
- 2009-04-27 UA UAA201014039A patent/UA102849C2/ru unknown
- 2009-04-27 SG SG10201408483QA patent/SG10201408483QA/en unknown
- 2009-04-27 KR KR1020137009925A patent/KR20130059442A/ko not_active Ceased
- 2009-04-27 WO PCT/US2009/041826 patent/WO2009134718A1/en not_active Ceased
- 2009-04-27 CN CN2009801149788A patent/CN102014923A/zh active Pending
- 2009-04-27 KR KR20107026587A patent/KR20110014162A/ko not_active Ceased
- 2009-04-27 CA CA2722753A patent/CA2722753C/en not_active Expired - Fee Related
- 2009-04-27 EA EA201401347A patent/EA032646B1/ru not_active IP Right Cessation
- 2009-04-27 DK DK09739520.6T patent/DK2293797T3/en active
- 2009-04-27 JP JP2011506497A patent/JP5791499B2/ja not_active Expired - Fee Related
- 2009-04-27 NZ NZ589533A patent/NZ589533A/en not_active IP Right Cessation
- 2009-04-27 ME MEP-2010-182A patent/ME01123B/me unknown
- 2009-04-27 EA EA201990835A patent/EA201990835A3/ru unknown
- 2009-04-27 EP EP09739520.6A patent/EP2293797B1/en not_active Not-in-force
- 2009-04-28 AR ARP090101513 patent/AR071516A1/es unknown
- 2009-04-28 CL CL2009001010A patent/CL2009001010A1/es unknown
-
2010
- 2010-10-20 IL IL208844A patent/IL208844A0/en unknown
- 2010-10-21 ZA ZA2010/07529A patent/ZA201007529B/en unknown
- 2010-10-27 NI NI201000183A patent/NI201000183A/es unknown
-
2013
- 2013-04-02 US US13/855,559 patent/US8735381B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009001010A1 (es) | Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea. | |
| ATE537833T1 (de) | Behandlung des mekoniumaspirationssyndroms mit östrogenen | |
| ES2671516T3 (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno | |
| AR071419A1 (es) | Composiciones y metodos de tratamiento del cancer de mama | |
| CO6220941A2 (es) | Progesterona para el tratamiento o prevencion del parto prematuro espontaneo | |
| CL2013003163A1 (es) | Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. | |
| JP2011518845A5 (enExample) | ||
| CL2012000166A1 (es) | Compuesto (11beta,17beta)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; y su uso para el tratamiento y/o la prevencion de fibroides uterinos, endometriosis, sangrados menstruales severos, meningiomas, cancer de mama hormonodependiente y de trastornos asociados a la menopausia, entre otros. | |
| AR048722A1 (es) | Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos | |
| ES2208518T3 (es) | Medio y metodo anticonceptivo hormonal. | |
| BR112012015016A8 (pt) | Formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação | |
| Guo et al. | Toxicity effects of a novel potent triple reuptake inhibitor, LPM570065, on the fertility and early embryonic development in Sprague-Dawley rats | |
| EA201792524A1 (ru) | Режим приема селективного модулятора рецептора прогестерона (sprm) | |
| CY1121190T1 (el) | Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης | |
| Marzieh et al. | Effects of steroid hormones on uterine tissue remodeling of mouse menopause model | |
| BRPI0511796A (pt) | derivado de propano-1, 3-diona ou seu sal | |
| AR040188A1 (es) | Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva | |
| Miura et al. | Effect of insulin and growth hormone on rat uterine RNA synthesis | |
| WO2020221277A1 (zh) | 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法 | |
| PT1267885E (pt) | Formulação contraceptiva masculina compreendendo noretisterona | |
| PE20090825A1 (es) | Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva | |
| AR072781A1 (es) | Composiciones que comprenden cdb-4124 y metodos de contracepcion masculina | |
| KANG et al. | Medical therapy of endometriosis to reduce the risk of recurrence | |
| UY29861A1 (es) | Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral | |
| CN104546870B (zh) | 一种避孕药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |